An innovative approach to preventing bleeds

in hemophilia B and hemophilia A with inhibitors

The clotting cascade is a series of steps, like a domino effect, where each domino represents a different clotting protein. When the dominoes fall properly, clotting occurs.

Finding balance may be a challenge for people living with hemophilia with inhibitors

Alhemo® helps keep blood in balance

Alhemo® with clot illustration

Helps the body create the right amount of thrombin

Alhemo® molecule illustration

Keeps thrombin levels consistent without peaks and troughs

Alhemo® molecule illustration

Works fast and exits the body quickly in 4 daysa

It’s important to take Alhemo® daily, especially during the first 4 weeks, to ensure you get the correct maintenance dose and stay protected from bleeding. Always use Alhemo® exactly as prescribed. Do not stop or miss doses without first consulting your healthcare provider, as this may reduce your protection against bleeding. To find the right maintenance dose for you, your provider will check Alhemo® levels in your blood. Additional blood tests may be done during treatment.

aAfter your Day 1 loading dose, the amount of Alhemo® builds up in the body to a stable amount around Day 4, and remains stable with daily maintenance doses. If you stop Alhemo®, 90% of it is expected to leave the body by the end of approximately 4 days after the last dose. The time for 50% of drug to leave the body is approximately 1 day.

See how Alhemo® works in the body

See the science behind the balance. This video breaks down how Alhemo® works in the clotting cascade.

For hemophilia B with inhibitors:

Clotting cascade without hemophilia illustration

Clotting cascade without hemophilia

  • Factor 9 is part of the clotting cascade that falls onto other dominoes to form clots and prevent bleeding.
  • A protein called tissue factor pathway inhibitor, or TFPI, is also part of the process. It blocks the rest of the cascade’s dominoes so there is not too much clotting.
Clotting cascade in hemophilia with inhibitors illustration

Clotting cascade in hemophilia B with inhibitors

  • In hemophilia B with inhibitors, the Factor 9 domino cannot fall onto the next domino, and TFPI still blocks the dominoes from falling on the other side of the cascade. When the dominoes do not fall, clots will not form, and bleeding may occur.
How Alhemo® works illustration

How Alhemo® works

  • Alhemo® stops TFPI from blocking the dominoes, so they can continue to fall, even without Factor 9 and with inhibitors.
Bleed prevention illustration

Bleed prevention

  • As a result, the domino cascade can be completed and a clot can form.

For hemophilia A with inhibitors:

Clotting cascade without hemophilia illustration

Clotting cascade without hemophilia

  • Factor 8 is part of the clotting cascade that falls onto other dominoes to form clots and prevent bleeding.
  • A protein called tissue factor pathway inhibitor, or TFPI, is also part of the process. It blocks part of the rest of the cascade so there is not too much clotting.

Clotting cascade in hemophilia A with inhibitors

  • In hemophilia A with inhibitors, the Factor 8 domino cannot fall onto the next domino and TFPI still blocks the dominoes from falling on the other side of the cascade. When the dominoes do not fall, clots will not form, and bleeding may occur.

How Alhemo® works

  • Alhemo® stops TFPI from blocking the dominoes so they can continue to fall, even without Factor 8 and with inhibitors.

Bleed prevention

  • As a result, the domino cascade can be completed and a clot can form.

Proven to prevent bleeds

Learn more about how Alhemo® works to reduce bleeds.

Discover how

Connect with us!

Want to learn more about Alhemo®? Get important email updates, information about patient support programs, and more.

Contact my RBCL
Show more Show less

Important Safety Information

What is the most important information I should know about Alhemo®?

  • It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding. This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo® exactly as prescribed by your healthcare provider (HCP). Do not stop using Alhemo® without talking to your HCP. If you miss doses or stop using Alhemo®, you may no longer be protected against bleeding
  • Your HCP may prescribe bypassing agents during treatment with Alhemo®. Carefully follow your HCP’s instructions regarding when to use on-demand bypassing agents, and the recommended dose and schedule for breakthrough bleeds

Do not use Alhemo® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo®.

Before using Alhemo®, tell your HCP about all of your medical conditions, including if you:

  • Have a planned surgery. Talk to your HCP about when to stop using Alhemo® and when to start it again if you have a planned surgery
  • Are pregnant, breastfeeding, or plan to become pregnant or to breastfeed. It is not known if Alhemo® may harm your unborn baby or if Alhemo® passes into your breast milk
    • Your HCP may do a pregnancy test before you start treatment with Alhemo®.
    • Females who are able to become pregnant, talk to your HCP about using effective birth control (contraception) methods during treatment with Alhemo® and for 7 weeks after ending treatment

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and supplements.

What are the possible side effects of Alhemo®?

Alhemo® may cause serious side effects, including:

  • Blood clots (thromboembolic events). Alhemo® may cause blood clots to form in blood vessels, such as in your arms, legs, heart, lung, brain, eyes, kidneys, or stomach. You may be at risk for getting blood clots if you use high or frequent doses of factor products or bypassing agents to treat breakthrough bleeds, or if you have certain conditions. Get medical help right away if you have any signs and symptoms of blood clots, including: swelling, warmth, pain, or redness of the skin; headache; trouble speaking or moving; eye pain or swelling; sudden pain in your stomach or lower back area; feeling short of breath or severe chest pain; confusion; numbness in your face; and problems with your vision
  • Allergic reactions. Alhemo® can cause allergic reactions, including redness of the skin, rash, hives, itching, and stomach-area (abdominal) pain. Stop using Alhemo® and get emergency medical help right away if you develop any signs or symptoms of a severe allergic reaction, including: itching on large areas of skin; trouble swallowing; wheezing; pale and cold skin; dizziness due to low blood pressure; redness or swelling of lips, tongue, face, or hands; shortness of breath; tightness of the chest; and fast heartbeat

The most common side effects of Alhemo® include: bruising, redness, bleeding, or itching at the site of injection, and hives. These are not all the possible side effects of Alhemo. Call your doctor for medical advice about side effects.

Please see Prescribing Information and Medication Guide for Alhemo®.

Alhemo® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Alhemo®?

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

  • It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age

What is Alhemo®?

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

  • It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age

Show more Show less
Show more Show less

What is Alhemo®?

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

  • It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age

What is Alhemo®?

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

  • It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age

Important Safety Information

What is the most important information I should know about Alhemo®?

  • It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding. This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo® exactly as prescribed by your healthcare provider (HCP). Do not stop using Alhemo® without talking to your HCP. If you miss doses or stop using Alhemo®, you may no longer be protected against bleeding
  • Your HCP may prescribe bypassing agents during treatment with Alhemo®. Carefully follow your HCP’s instructions regarding when to use on-demand bypassing agents, and the recommended dose and schedule for breakthrough bleeds

Do not use Alhemo® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo®.

Important Safety Information

What is the most important information I should know about Alhemo®?

  • It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding. This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo® exactly as prescribed by your healthcare provider (HCP). Do not stop using Alhemo® without talking to your HCP. If you miss doses or stop using Alhemo®, you may no longer be protected against bleeding
  • Your HCP may prescribe bypassing agents during treatment with Alhemo®. Carefully follow your HCP’s instructions regarding when to use on-demand bypassing agents, and the recommended dose and schedule for breakthrough bleeds

Do not use Alhemo® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo®.

Before using Alhemo®, tell your HCP about all of your medical conditions, including if you:

  • Have a planned surgery. Talk to your HCP about when to stop using Alhemo® and when to start it again if you have a planned surgery
  • Are pregnant, breastfeeding, or plan to become pregnant or to breastfeed. It is not known if Alhemo® may harm your unborn baby or if Alhemo® passes into your breast milk
    • Your HCP may do a pregnancy test before you start treatment with Alhemo®.
    • Females who are able to become pregnant, talk to your HCP about using effective birth control (contraception) methods during treatment with Alhemo® and for 7 weeks after ending treatment

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and supplements.

What are the possible side effects of Alhemo®?

Alhemo® may cause serious side effects, including:

  • Blood clots (thromboembolic events). Alhemo® may cause blood clots to form in blood vessels, such as in your arms, legs, heart, lung, brain, eyes, kidneys, or stomach. You may be at risk for getting blood clots if you use high or frequent doses of factor products or bypassing agents to treat breakthrough bleeds, or if you have certain conditions. Get medical help right away if you have any signs and symptoms of blood clots, including: swelling, warmth, pain, or redness of the skin; headache; trouble speaking or moving; eye pain or swelling; sudden pain in your stomach or lower back area; feeling short of breath or severe chest pain; confusion; numbness in your face; and problems with your vision
  • Allergic reactions. Alhemo® can cause allergic reactions, including redness of the skin, rash, hives, itching, and stomach-area (abdominal) pain. Stop using Alhemo® and get emergency medical help right away if you develop any signs or symptoms of a severe allergic reaction, including: itching on large areas of skin; trouble swallowing; wheezing; pale and cold skin; dizziness due to low blood pressure; redness or swelling of lips, tongue, face, or hands; shortness of breath; tightness of the chest; and fast heartbeat

The most common side effects of Alhemo® include: bruising, redness, bleeding, or itching at the site of injection, and hives. These are not all the possible side effects of Alhemo. Call your doctor for medical advice about side effects.

Please see Prescribing Information and Medication Guide for Alhemo®.

Alhemo® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Important Safety Information

What is the most important information I should know about Alhemo®?

  • It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding. This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo® exactly as prescribed by your healthcare provider (HCP). Do not stop using Alhemo® without talking to your HCP. If you miss doses or stop using Alhemo®, you may no longer be protected against bleeding
  • Your HCP may prescribe bypassing agents during treatment with Alhemo®. Carefully follow your HCP’s instructions regarding when to use on-demand bypassing agents, and the recommended dose and schedule for breakthrough bleeds

Do not use Alhemo® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo®.

Before using Alhemo®, tell your HCP about all of your medical conditions, including if you:

  • Have a planned surgery. Talk to your HCP about when to stop using Alhemo® and when to start it again if you have a planned surgery
  • Are pregnant, breastfeeding, or plan to become pregnant or to breastfeed. It is not known if Alhemo® may harm your unborn baby or if Alhemo® passes into your breast milk
    • Your HCP may do a pregnancy test before you start treatment with Alhemo®.
    • Females who are able to become pregnant, talk to your HCP about using effective birth control (contraception) methods during treatment with Alhemo® and for 7 weeks after ending treatment

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and supplements.

What are the possible side effects of Alhemo®?

Alhemo® may cause serious side effects, including:

  • Blood clots (thromboembolic events). Alhemo® may cause blood clots to form in blood vessels, such as in your arms, legs, heart, lung, brain, eyes, kidneys, or stomach. You may be at risk for getting blood clots if you use high or frequent doses of factor products or bypassing agents to treat breakthrough bleeds, or if you have certain conditions. Get medical help right away if you have any signs and symptoms of blood clots, including: swelling, warmth, pain, or redness of the skin; headache; trouble speaking or moving; eye pain or swelling; sudden pain in your stomach or lower back area; feeling short of breath or severe chest pain; confusion; numbness in your face; and problems with your vision
  • Allergic reactions. Alhemo® can cause allergic reactions, including redness of the skin, rash, hives, itching, and stomach-area (abdominal) pain. Stop using Alhemo® and get emergency medical help right away if you develop any signs or symptoms of a severe allergic reaction, including: itching on large areas of skin; trouble swallowing; wheezing; pale and cold skin; dizziness due to low blood pressure; redness or swelling of lips, tongue, face, or hands; shortness of breath; tightness of the chest; and fast heartbeat

The most common side effects of Alhemo® include: bruising, redness, bleeding, or itching at the site of injection, and hives. These are not all the possible side effects of Alhemo. Call your doctor for medical advice about side effects.

Please see Prescribing Information and Medication Guide for Alhemo®.

Alhemo® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Alhemo®?

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

  • It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age

What is Alhemo®?

Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.

  • It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age

You are about to leave alhemo.com, a Novo Nordisk website

Click “Continue” to leave this site and come back to visit us another time. Click “Return to site” to stay and learn more about Alhemo.

Continue

You are about to leave alhemo.com, a Novo Nordisk website

Click “Continue” to leave this website. Novo Nordisk is not responsible for content that follows. Please come back to visit us another time.

Click “Return to site” to stay and learn more about Alhemo.

Continue